Analysts Offer Insights on Healthcare Companies: Teleflex (TFX), Sanofi (OtherSNYNF) and Neurocrine (NBIX)


Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teleflex (TFX), Sanofi (SNYNF) and Neurocrine (NBIX).

Teleflex (TFX)

Needham analyst Michael Matson maintained a Buy rating on Teleflex today and set a price target of $445.00. The company’s shares closed last Friday at $400.02, close to its 52-week high of $414.72.

According to TipRanks.com, Matson is a 5-star analyst with an average return of 15.4% and a 69.1% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Cardiovascular Systems.

Currently, the analyst consensus on Teleflex is a Strong Buy with an average price target of $450.75, which is a 13.1% upside from current levels. In a report issued on January 27, JMP Securities also maintained a Buy rating on the stock with a $440.00 price target.

See today’s analyst top recommended stocks >>

Sanofi (SNYNF)

In a report released today, Peter Welford from Jefferies maintained a Buy rating on Sanofi, with a price target of EUR110.00. The company’s shares closed last Thursday at $94.28.

Welford has an average return of 7.1% when recommending Sanofi.

According to TipRanks.com, Welford is ranked #529 out of 7271 analysts.

Currently, the analyst consensus on Sanofi is a Moderate Buy with an average price target of $116.45, representing a 23.5% upside. In a report issued on January 26, J.P. Morgan also maintained a Buy rating on the stock with a EUR93.00 price target.

Neurocrine (NBIX)

In a report released today, Joseph Stringer from Needham maintained a Hold rating on Neurocrine. The company’s shares closed last Friday at $114.64.

According to TipRanks.com, Stringer is a 3-star analyst with an average return of 23.5% and a 66.7% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Annexon Biosciences, and Stoke Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Neurocrine with a $123.79 average price target, implying an 8.1% upside from current levels. In a report issued on February 1, Mizuho Securities also maintained a Hold rating on the stock with a $117.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts